A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of single escalating doses PF-06342674.

Key facts

Study ID

NCT01740609

Run by

Pfizer

People needed

80

Starts

2012-11-01

Expected to finish

2014-06-01

Last updated by the study team

2014-06-19

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male subjects and female of non-childbearing potential subjects between the ages of 18 and 55.
• BMI between 18.5 to 32 kg/m2.
• Total body weight ≥40 kg and ≤120 kg.

You may not qualify if…

• Previous treatment with an antibody within 6 months prior to Day 1.
• Pregnant or nursing females; females of childbearing potential.
• History of sensitivity to heparin or heparin-induced thrombocytopenia.

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.